trending Market Intelligence /marketintelligence/en/news-insights/trending/2UWMnPwk1NRi-UhSMvBV5Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca-Daiichi Sankyo breast cancer drug gets US FDA priority tag

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AstraZeneca-Daiichi Sankyo breast cancer drug gets US FDA priority tag

AstraZeneca PLC and Daiichi Sankyo Co. Ltd. said the U.S. Food and Drug Administration granted priority review to their breast cancer drug trastuzumab deruxtecan.

The U.S. regulator accepted the application to review the therapy for treating human epidermal growth factor receptor 2-positive breast cancer which has spread across the body or has metastasized.

The FDA is expected to decide on the therapy's approval by the second quarter of 2020.

In May, trastuzumab deruxtecan was shown to shrink tumors in heavily treated patients with metastatic HER2-positive breast cancer in a phase 2 trial called Destiny-Breast01.

Cambridge, U.K.-based AstraZeneca and Tokyo's Daiichi Sankyo are collaborating on the development and commercialization of trastuzumab deruxtecan, or DS-8201, under a global deal the companies entered in March. The British pharmaceutical giant agreed to pay the Japanese drugmaker $1.35 billion up front, with contingent payments of up to $5.55 billion.

The drug previously received breakthrough therapy and fast track designations from the FDA for treating patients with HER2-positive breast cancer that is locally advanced breast cancer or that has spread to other organs.

SNL Image